Direct Comparison with MSD's Varivax

GC Green Cross announced on March 27 that on March 25, its clinical phase 3 investigational new drug (IND) application for its varicella vaccine "Varicellazou" 2-dose (two-dose) regimen received approval from the Vietnamese Ministry of Health.


The company explained that this approval was granted more quickly than initially planned, thanks to proactive communication with local regulatory authorities following the IND submission in November of last year. The phase 3 clinical trial for GC Green Cross’s Varicellazou 2-dose regimen received IND approval in Thailand in October last year, and the first patient was enrolled (FPI) on March 17.

GC Green Cross headquarters in Yongin-si, Gyeonggi Province. GC Green Cross

GC Green Cross headquarters in Yongin-si, Gyeonggi Province. GC Green Cross

View original image

The main objective of the study is to evaluate the immunogenicity and safety of the two-dose regimen of Varicellazou in healthy children aged 12 months to 12 years, with the goal of obtaining clinical results by next year. The study is designed as a head-to-head clinical trial comparing Varicellazou directly with Varivax, a leading global product from Merck (MSD) in the United States.


GC Green Cross plans to enter the global varicella vaccine two-dose market starting with Southeast Asian countries from 2028.



Lee Jaewoo, Head of Development at GC Green Cross, said, "Through the successful execution of the clinical trial, we will demonstrate the competitiveness of Varicellazou in the globally standardized two-dose environment."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing